Finance

Lists
Q3 2026 earnings • released • EPS beat +46.28% • Revenue beat +5.25%
See results
MRVI:NASDAQ
Maravai Lifesciences Holdings Inc
$7.52
+7.74%
(+0.54) 1D
$7.67
+1.99% (+0.15)
After hours
Closed: Nov 6, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MRVI...
Open
$7.02
High
$7.62
Low
$7.01
Mkt. cap
1.95B
Avg. vol.
2.55M
Volume
1.94M
52-wk high
$9.42
52-wk low
$2.54
EPS
-$0.45
Beta
0.61
Shares outstanding
148.99M
No. of employees
415
Open
$7.02
High
$7.62
Low
$7.01
Mkt. cap
1.95B
Avg. vol.
2.55M
Volume
1.94M
52-wk high
$9.42
52-wk low
$2.54
EPS
-$0.45
Beta
0.61
Shares outstanding
148.99M
No. of employees
415
News stories
From web sources and news partners
About Maravai Lifesciences Holdings Inc
CEO-
Employees415
Founded2014
Headquarters-
SectorHealth Care
Industry-
Websitemaravai.com
Analyst ratings
Based on 4 analysts giving stock ratings to MRVI in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MRVI in the last 3 months.
Highest
Current $7.52
$10.00 (+32.98%)
Average
$9.13 (+21.41%)
Lowest
$8.00 (+6.38%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matt Hewitt
Craig-Hallum
Buy
Maintained
$10.00
+33%
11/05/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
$9.50
+26.3%
11/05/2026
Brendan Smith
TD Cowen
Buy
Initiated
$9.00
+19.7%
10/05/2026
Unknown Analyst
UBS
Hold
Initiated
$8.00
+6.4%
09/08/2026
Doug Schenkel
UBS
Hold
Maintained
$8.00
+6.4%
09/09/2026
Evan Stampler
Wells Fargo
Buy
Maintained
$6.50
-13.6%
08/07/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$6.50
-13.6%
08/07/2026
Matt Larew
William Blair
Hold
Reiterated
-
-
08/07/2026
Subbu Nambi
Guggenheim
Hold
Maintained
-
-
05/11/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
$6.00
-20.2%
05/08/2026
Catherine Ramsey Schulte
Robert W. Baird
Hold
Maintained
$3.00
-60.1%
02/26/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$5.00
-33.5%
02/26/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$0.03 / -$0.06
+46.28%beat
Revenue / Est. (USD)
45.85M / 43.56M
+5.25%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
49.87M
65.84M
51.44M
45.85M
Cost of goods sold
35.32M
32.14M
30.79M
29.66M
Cost of revenue
35.32M
32.14M
30.79M
29.66M
Research and development expenses
3.79M
3.89M
3.70M
3.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
30.38M
29.09M
32.07M
30.50M
Operating expense
34.17M
32.98M
35.77M
33.89M
Total operating expenses
69.50M
65.12M
66.56M
63.55M
Operating income
-19.63M
720.00K
-15.12M
-17.70M
Other non operating income
-43.00K
-494.00K
-52.00K
-27.00K
EBT including unusual items
-63.01M
-6.53M
-21.80M
-24.08M
EBT excluding unusual items
-23.84M
-3.65M
-18.82M
-21.16M
Income tax expense
6.00K
-151.00K
-171.00K
-75.00K
Effective tax rate
-0.01%
2.31%
0.78%
0.31%
Other operating expenses
-
-
-
-
Net income
-35.68M
-3.73M
-12.42M
-13.84M
Net profit margin
-71.55%
-5.67%
-24.14%
-30.18%
Earnings per share
-0.04
0.01
-0.02
-0.03
Interest and investment income
2.38M
1.87M
1.16M
598.00K
Interest expense
-6.56M
-5.75M
-4.81M
-4.03M
Net interest expenses
-4.17M
-3.88M
-3.65M
-3.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.18M
12.09M
-3.34M
-5.92M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps